"The US Food and Drug Administration (FDA) has approved an expanded indication for onabotulinum toxin A (Botox, Actavis) for the treatment of adults with upper limb spasticity, according to a company news release.
The expanded i"...
Heparin sodium should not be used in patients:
- With hypersensitivity to heparin;
- With an uncontrollable active bleeding state (see WARNINGS), except when this is due to disseminated intravascular coagulation;
- With inability to perform suitable blood-coagulation tests, e.g., whole-blood clotting time, partial thromboplastin time, etc. at required intervals. There is usually no need to monitor effect of low-dose heparin in patients with normal coagulation parameters.
Last reviewed on RxList: 1/10/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Lok Pak Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.